Skip to main content
Equibles
GH logo

GH · Guardant Health, Inc. · Metrics

Track GH — free

Use GH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$157.67 +6.80 (+4.50%) Play latest call Q3 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Market Cap
$20.41B
Shares
135.29M
Volume · Nov 9 682.38K Avg daily vol (3M) 1.99M

GH metrics

90 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$150.87
Market cap
$20.41B

Price action

23 metrics
Price change (1W)
-15.6%
Price change (30D)
-9.9%
Price change (3M)
-10.5%
Price change (6M)
+57.6%
Price change (YTD)
+47.7%
Price change (1Y)
+56.7%
Trailing year
Price change (5Y)
+36.9%
52-week high
$187.22
52-week low
$78.60
Change from 52-week high
-19.4%
Change from 52-week low
+91.9%
Annualized volatility
52.7%
Annualized volatility (3M)
49.1%
Implied volatility (30D)
61.3%
IV rank (1Y)
22.0
IV percentile (1Y)
44.6
Beta
1.3
RSI (14D)
36.5
Price vs SMA 50
-10.9%
Price vs SMA 200
+14.5%
Avg volume (3M)
1.99M
Relative volume
2.8
Average dollar volume
$333.00M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
135.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
16.3×
reciprocal yield 6.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
16.0×
reciprocal yield 6.3%
P / book
—
FCF yield
-1.1%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
9.5×
reciprocal yield 10.5%
EV / revenue historical average (5Y)
10.0×
reciprocal yield 10.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
65.2%
Operating margin
-39.4%
Trailing 12 months
Net margin
-37.9%
Gross profit (TTM)
$833.70M
Operating profit (TTM)
−$504.04M
Net income (TTM)
−$485.07M
Trailing 12 months
Diluted EPS (TTM)
$-3.69
FCF margin
-18.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$9.69
Gross profit per diluted share (TTM)
$6.32
Operating profit per diluted share (TTM)
$-3.82
EBITDA per diluted share (TTM)
$-3.53
Net income per diluted share (TTM)
$-3.68
Operating cash flow per diluted share (TTM)
$-1.32
Free cash flow per diluted share (TTM)
$-1.76
Capital expenditures per diluted share (TTM)
$0.45
R&D per diluted share (TTM)
$2.93
Stock compensation per diluted share (TTM)
$1.60
Book value per share
$-0.76

Growth

11 metrics
Revenue growth YoY
+36.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.28B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.7%
Year over year · more shares
Revenue CAGR (3Y)
+29.8%
Revenue CAGR (5Y)
+27.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-25.7%
Debt / equity
—
Current ratio
3.6
EBITDA (TTM)
−$464.81M
Free cash flow (TTM)
−$232.15M
Quick ratio
3.3
Interest coverage
-96.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$475.56M
Latest balance sheet
Cash & equivalents
$1.03B
Total assets
$1.89B
Total debt
$1.50B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$173.48M
Capital expenditures (TTM)
$58.67M
R&D (TTM)
$386.67M
SG&A (TTM)
—
Stock compensation (TTM)
$210.96M
R&D / revenue
30.2%
Stock compensation / revenue
16.5%

Ownership (13F)

9 metrics
13F filers
607
13F filer change QoQ
+113
Institutional ownership
100.3%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.5%
Holder tenure
14.6
Price vs estimated holder cost
+107.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.7%

Short interest

3 metrics
Short interest
8.6%
Latest settlement · 6.7 days to cover
Days to cover
6.7d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$17.38M
Insider-sentiment score
9 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 297 filings 264 filers Visit website Investor relations